Quiz 5 Flashcards
tenofovir + emtricitabine 1
Truvada. Nucelotide RTI + nucleoside RTI. HIV-1, pre-exposure prophylaxis (PreP) of HIV-1 infection.
tenofovir + emtricitabine 2
MOA: Nucleoside and nucleotide reverse transcriptase inhibitor combination; each drug interferes with HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication
BBW: Lactic acidosis/severe hepatomegaly with steatosis; post-treatment acute exacerbation of Hep B; risk of drug resistance with use for PreP
SE: abnormal dreams, depression, diarrhea, dizziness, fatigue, headache, insomnia, nausea, and rash
tenofovir + alafenamide + emtricitabine 1
Brand: Descovy
Class: nucelotide RTI + nucleoside RTI
Indication: HIV (in combo w/ other antiretrovirals)
tenofovir + alafenamide + emtricitabine 2
MOA: each drug interferes with HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication
BBW: Lactic acidosis/severe hepatomegaly with steatosis; post-treatment acute exacerbation of Hep B
SE: nausea
tenofovir + alafenamide + emtricitabine + rilpivirine 1
Brand: Odefsey
Class: nucelotide RTI + nuceloside RTI + NNRTI
Indication: HIV
tenofovir + alafenamide + emtricitabine + rilpivirine 2
MOA: Tenofovir alafenamide & emtricitabine - compete with natural substrates and incorporate into viral DNA, resulting in termination of the DNA chain. Rilpivirine - noncompetitively incorporates into viral DNA & terminates the DNA chain
BBW: Lactic acidosis/severe hepatomegaly with steatosis; post-treatment acute exacerbation of Hep B
SE: nausea, HA, somnolence
tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat 1
Brand: Genvoya
Indication: HIV
Class: nucleotide RTI + nuceloside RTI + integrase inhibitor + CYP450 inhibitor
tenofovir alafenamide + emtricitabine + elvitegravir + cobicista2
MOA: Tenofovir alafenamide & emtricitabine - compete with natural substrates and incorporate into viral DNA, resulting in termination of the DNA chain. Elvitegravir - inhibits the catalytic activity of integrase, preventing integration of the proviral gene into human DNA. Cobicistat - inhibits enzymes of the CYP3A subfamily & enhances systemic exposure to elvitegravir.
BBW: lactic acidosis, severe hepatomegaly, postreatment exacerbation of hepatitis B
SE: decreased bone mineral density, nausea
abacavir + lamivudine 1
Brand: Epzicom
Class: both are nucleoside RTIs
Indication: HIV
abacavir + lamivudine 2
ranscriptase inhibitor combination
BBW: Hypersensitivity reactions (esp. w/ HLA-B*5701 allele); Lactic acidosis/severe hepatomegaly with steatosis; post-treatment exacerbations of Hep B
SE: depression, headache, insomnia
abacavir + lamivudine + dolutegravir 1
Brand: Triumeq
Class: nucleoside RTI + nucleoside RTI + integrase inhibitor
Indication: HIV.
abacavir + lamivudine + dolutegravir 2
MOA: Abacavir & lamivudine - inhibit HIV-1 reverse transcriptase; they get incoporated into viral DNA and halt replication. Dolutegravir - inhibits the catalytic activity of integrase, thus preventing integration of the proviral gene into human DNA.
BBW: Hypersensitivity reactions (esp. in pts. w/ HLA-B*5701 allele); Lactic acidosis/severe hepatomegaly with steatosis; post-treatment exacerbations of Hep B
SE: hypersensitivity rxn to abacabvir component
lamivudine + zidovudine 1
Brand: Combivir
Class: both are nucleoside RTIs
Indication: HIV
lamivudine + zidovudine 2
MOA: both act synergistically to inhibit reverse transcriptase b/c they are phosphorylated in the cell & are incorporated into the DNA chain
BBW: hematologic toxicity in advanced HIV-1; Lactic acidosis/severe hepatomegaly with steatosis; post-treatment exacerbations of Hep B
SE: HA, N/V/D, nasal symptoms, cough dizziness, insomnia, neuropathy, sleep disorder, musculoskeletal pain,
dolutegravir 1
Brand: Tivicay
Class: Integrase Inhibitor
Indication: HIV